论文部分内容阅读
最新研究表明,不管哮喘的严重程度如何,常规使用吸入性皮质类固醇(ICS)和限用短效β_2拮抗剂(ISABA)可减少哮喘复发住院的风险。来自于加拿大Alberta大学的Ambikaipakan Senthilselvan教授及其同事报道说,该结果支持此前认定的“过多使用ISABA可增加哮喘发病和死亡”的观点。这项研究涉及30 000例患者在近10年内至少5次就医于哮喘相关诊室。研究人员通过对“Saskatchewan健康数据库”的资料分析以确定ICS和ISABA的使用与哮喘导致的住院频率。重度哮喘被定义为每3个月至少一次就诊于哮喘相关科室医生；不符合该定义的患者被视为并不严重；ISABA或ICS使用高和低被分别定义为每月用量超过1罐或少于1罐。
Recent research shows that routine use of inhaled corticosteroids (ICS) and the use of short-acting beta 2 antagonists (ISABA) reduce the risk of recurrent asthma hospitalizations, regardless of the severity of the asthma. Professor Ambikaipakan Senthilselvan from Alberta University in Canada and colleagues report that the results support the previously asserted belief that “excessive use of ISABA increases asthma morbidity and mortality”. The study involved 30,000 patients seeking treatment for asthma-related clinics at least 5 visits in the last 10 years. The researchers analyzed data from the Saskatchewan Health Database to determine how often ICS and ISABA were used and the frequency of hospitalizations due to asthma. Severe asthma is defined as the number of asthma-related department physicians who visit the department of asthma at least once every 3 months; patients who do not meet this definition are considered not serious; use of high or low ISABA or ICS is defined as monthly consumption of less than 1 canister or less per month In 1 can.